Asset
TEBENTAFUSP
Immunocore Holdings plc American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02570308 | phase1_2 | completed | 2016-02-29 | 2020-03-20 | Immunocore Ltd | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma |
| NCT02889861 | phase2 | terminated | 2017-01-11 | 2019-04-22 | Immunocore Ltd | IMCgp100-401 Rollover Study |
| NCT02535078 | phase1_2 | withdrawn | 2015-11-01 | 2023-06-19 | Immunocore Ltd | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma |
| NCT04262466 | phase1_2 | active_not_recruiting | 2020-02-25 | 2026-10-01 | Immunocore Ltd | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors |
| NCT03070392 | phase2 | completed | 2017-10-16 | 2020-10-13 | Immunocore Ltd | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma |
FDA applications (0)
This company has no applications containing this asset.